SCHEMBL3398669

SCHEMBL3398669

COc1ccc(Nc2ncc(NC(=O)c3ccc(N)c(N)c3)s2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 2/20 0.49
CSNK2A1 P68400 2/20 0.49
TUBB8B A6NNZ2 1/20 0.49
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49
TUBB4B P68371 1/20 0.49
TUBB3 Q13509 1/20 0.49
TUBB2A Q13885 1/20 0.49
TUBB8 Q3ZCM7 1/20 0.49
TUBB6 Q9BUF5 1/20 0.49
TUBB2B Q9BVA1 1/20 0.49
TUBB1 Q9H4B7 1/20 0.49
SPHK2 Q9NRA0 1/20 0.49
SPHK1 Q9NYA1 1/20 0.49
NPC1 O15118 7/20 0.49
MEN1 O00255 6/20 0.49
KMT2A Q03164 6/20 0.49
RAB9A P51151 5/20 0.46
TP53 P04637 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3397155 0.89 CSNK2A2 (0.60) CSNK2A2CSNK2A1NPC1MEN1KMT2A
SCHEMBL3393588 0.84 CSNK2A2 (0.55) CSNK2A2CSNK2A1NPC1KMT2ARAB9A
SCHEMBL3394933 0.83 CSNK2A2 (0.60) CSNK2A2CSNK2A1NPC1MEN1KMT2A
SCHEMBL3396818 0.82 CSNK2A2 (0.56) CSNK2A2CSNK2A1NPC1MEN1KMT2A
SCHEMBL3396383 0.82 CSNK2A2 (0.55) CSNK2A2CSNK2A1NPC1MEN1KMT2A
SCHEMBL15559615 0.81 TNIK (0.68) CSNK2A2CSNK2A1TUBB8BTUBB4ATUBB
SCHEMBL3393872 0.81 CSNK2A2 (0.52) CSNK2A2CSNK2A1NPC1MEN1KMT2A
SCHEMBL3397310 0.80 CSNK2A2 (0.56) CSNK2A2CSNK2A1NPC1MEN1KMT2A
SCHEMBL3397141 0.80 CSNK2A2 (0.51) CSNK2A2CSNK2A1NPC1MEN1KMT2A
SCHEMBL3393212 0.80 TNIK (0.56) CSNK2A2CSNK2A1NPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216795-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216795-A1 TNIK INHIBITOR AND THE USE TNIK, TNNI3K, TNK1 CSNK2A2 18/4885CSNK2A1 24/4885TUBB8B 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.